ClinicalTrials.gg
RecruitingNCT07068490PCAB-PCIUpdated Jul 16, 2025

Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

An observational study in Coronary Artery Disease, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Samsung Medical Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.

Planned enrollment
4th of 10
100,000 · median 16,487
Started
2024
with 2 others
Observational
10 of 31
4 open now
Primary completion
2025-12
later than 2 of 13 live
Registered
29th of 31
by date

Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2024, is one of 10 observational ones, reaches primary completion later than 2 of the 13 other live ones, and was the 29th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Coronary Artery Disease by Samsung Medical Center, or all of them as a file.
02

Study summary

Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.

Read the detailed description

To evaluate the efficacy and safety of routine P-CAB use in patients with coronary artery disease who underwent PCI and maintain DAPT, as compared to guideline-directed proton pump inhibitor (PPI) usage.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • percutaeneous coronary intervention
  • dual antiplatelet therapy
  • gastrointestinal protection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with coronary artery disease who underwent PCI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who underwent PCI
  • Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin
  • No use of PCAB, PPI, or an H2-receptor within the past month

Exclusion criteria

Exclusion Criteria:

  • Patients with low GI bleeding risk are taken on PPI
  • Patients with high GI bleeding risk do not take PPI
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Routine use of P-CAB

    All-comer patients with P-CAB

    Drug: Routine use of P-CAB on DAPT

  • Guideline-directed GI protection strategy

    Use of PPI or not according to GI bleeding risk

    Drug: Guideline Directed Medical Therapy

Interventions

  • DrugRoutine use of P-CAB on DAPT

    This group received P-CAB with DAPT after PCI.

  • DrugGuideline Directed Medical Therapy

    This group received PPI or not with DAPT after PCI according to GI bleeding risk.

06

What researchers measure

Primary outcomes

  1. Major GI bleeding

    Major GI bleeding requiring transfusion

    Time frame: at 1 year

Secondary outcomes

  1. Clinically relevant GI bleeding

    Clinically relevant GI bleeding

    Time frame: At 1 year

  2. Major adverse cardiac event

    A composite of cardiovascular death, myocardial infarction, and repeat revascularization

    Time frame: At 1 year

  3. Cardiovascular death

    Cardiovascular death

    Time frame: At 1 year

  4. Myocardial infarction

    Myocardial infarction

    Time frame: At 1 year

  5. Repeat revascularization

    Repeat revascularization

    Time frame: At 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Dec 2025, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2025
First posted
Jul 16, 2025
StartActual
Oct 22, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07068490
Responsible party
Ki Hong Choi (Associate Professor, Samsung Medical Center) — Principal investigator
First posted
Jul 16, 2025
Start date
Oct 22, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jul 16, 2025

Study contacts

Ki Hong Choi, MD, PhD
Contact
cardiokh@gmail.com
82-2-3410-3419
Danbee Kang, PhD
Contact
dbee.kang@gmail.com
82-2-2148-7197
KI HONG CHOI, MD, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion